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Since the beginning of the 1990s, an increase in the number
of nosocomial infections caused by Gram-positive bacteria has
been recorded [1, 2]. With the emergence of glycopeptide
intermediately susceptible staphylococci and of glycopeptide-
resistant enterococci, the limits of the e¤cacy of the currently
licensed antimicrobial agents can be seen [3^5]. Therefore,
there is an urgent need for therapeutic alternatives. One of the
newer antibacterials with a spectrum of activity against Gram-
positive bacteria is linezolid, which is an oxazolidinone. Line-
zolid inhibits protein synthesis by preventing formation of the
initiation complex consisting of 305 ribosomes, mRNA, the
initiation factors IF2 and IF3 and f-Met-tRNA [6, 7]. Based
on pharmacokinetic data, the preliminary susceptibility
breakpoint for linezolid is R8  mg/L [8]. According to pre-
vious reports, mutants of Staphylococus aureus for which the
MICs of linezolid exceed this concentration are rare [9].
In this study we have investigated the in vitro activity of
linezolid against genotypically distinct strains of methicillin-
susceptible and methicillin-resistant S. aureus and coagulase-
negative staphylococcal species. Furthermore, we have tested
S. aureus strains exhibiting di¡erent spontaneous mutability
for the presence of linezolid resistance in populations cultured
in vitro.
Twenty-six methicillin-sensitive S. aureus strains from
sporadic infections, representing the major clonal groups of
this species (for description of strains and typing seeWitte et al
[10]), as well as 219 S aureus strains from di¡erent kinds of epi-
demiologically unrelated nosocomial infections which had
been sent to the authors' laboratory for typing from clinical
laboratories in Germany in 1998, were analyzed.These isolates
exhibit di¡erent SmaI-macrorestriction patterns.
MRSA isolates were attributed to the known clonal groups
of epidemic strains according to molecular typing patterns as
previously described [11] (one isolate per hospital has been
included; for an overview on dissemination of epidemic
MRSA in Germany seeWitte et al. [11]).
For S. aureus strains checked for spontaneous resistance
mutations, 705/92, PS55, 8325, PS96 and PS95 are representa-
tives of the di¡erent clonal groups of the species S. aureus [10],
and 2707/97, 1678/78, 134/93, 1000/93, 994/93 and 1150/93 are
reference strains of epidemic MRSA belonging to di¡erent
clonal groups (for details seeWitte et al [12]).
Table  1 Minimum inhibitory concentrations of linezolid for methicillin-susceptible and methicillin-resistant S. aureus
MIC (mg/L) of linezolid
Characteristics/origin of strains n 0.25 0.5 1.0 2.0 4.0
Methicillin-sensitive S. aureus
Reference strains for different clonal groups 26 0 6 9 11 0
Strains from sporadic nosocomial infections 219 0 5 48 166 0
Epidemic MRSA
Northern German MRSA 7 0 4 3 0
Hannover area MRSA (group III)
Southern German MRSA 16 0 6 10 0
Berlin MRSA 20 0 3 17 0
Barnim MRSA 11 0 11 0
MRSA belonging to clonal group I 4 0 1 2 1 0
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Apart from animal isolates of S. caprae, S. simulans, S. sciuri
and S. intermedius and isolates of S. saprophyticus originating
from urinary tract infections, all other coagulase-negative sta-
phylococci were isolated from blood cultures from di¡erent
hospitalized patients (exclusion of copy strains).
Minimum inhibitory concentrations were determined by
microbroth dilution assay according to NCCLS guidelines
[13].
For the screening of in vitro cultured populations of S. aur-
eus for the presence of mutants resistant to antibacterial agents,
Table  2 Minimum inhibitory concentrations of linezolid for coagulase-negative staphylococci
MIC (mg/L) of linezolid
Species n 0.25 0.5 1.0 2.0
S. epidermidis, MRSEa 54 27 26 1
S. epidermidis, MSSEa 20 1 8 10 1
S. hemolyticus (oxa-r)a 81 2 23 50 6
S. hemolyticus (oxa-s) 8 4 3 1
S. saprophyticusb 6 1 1 4
S. warneria 5 2 1 2
S. hominisa 8 2 5 1
S. auricularisa 1 1
S. cohniia 1 1
S. capraec 2 2
S. lugdunensisa 2 1 1
S. kloosia 1 1
S. sciuri 3 3
S. simulansc 3 2 1
S. intermediusc 2 1 1
Total 197 4 72 103 18
aFrom blood cultures; bfrom urinary tract infections; cstrains of animal origin.
Table  3 Frequencies of spontaneous mutants resistant to rifampicin, trimethoprim and linezolid in in vitro populations of MSSA and MRSA
Mutant frequencies in vitro
Clonal group Strain Resistance phenotype Rif-s 4 Rif-r Tmp-s 4 Tmp-r Lin-s 4 Lin-r
I 705/92 PEN <  10ÿ10 <  10ÿ10 <  10ÿ10
2702/97 PEN, OXA, CIP 6    10ÿ8 1.4    10ÿ6 <  10ÿ10
II PS55 PEN 5    10ÿ10 <  10ÿ10 <  10ÿ10
1678/98 PEN, OXA, ERY, CLI, CIP 8    10ÿ8 7    10ÿ10 <  10ÿ10
III 8325 Sensitive 1    10ÿ9 <  10ÿ10 <  10ÿ10
PS84 PEN, ERY, CLI, OTE <  10ÿ10 <  10ÿ10 <  10ÿ10
134/94 PEN, OXA, GEN, ERY, CLI, OTE, RAM, CIP ND <  10ÿ10 <  10ÿ10
1000/93 PEN, OXA, GEN, ERY, CLI, OTE, SXT, CIP 1.6    10ÿ9 ND <  10ÿ10
994/93 PEN, OXA, GEN, ERY, CLI, OTE, SXT, CIP <  10ÿ10 ND <  10ÿ10
IV PS96 PEN <  10ÿ10 <  10ÿ10 <  10ÿ10
V PS95 PEN 5    10ÿ10 <  10ÿ10 <  10ÿ10
1150/93 PEN, OXA, CIP 7    10ÿ7 1.7    10ÿ6 <  10ÿ10
NAa 131/98 3    10ÿ10 3    10ÿ10 <  10ÿ10
aNA, not assigned to a clonal group; ND, not done.
CIP, cipro¯oxacin; CLI, clindamycin; ERY, erythromycin; GEN, gentamicin; OTE, oxytetracyclin; OXA, oxacillin; RAM, rifampicin; SXT,
sulfamethoxazol/trimethoprim.
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aliquots from overnight cultures in Isosensitest broth
(Oxoid,Wesel, Germany) incubated at 37  Cwith shaking for
24  h were plated on di¡erent selective Isosensitest agar plates
(Oxoid) containing rifampicin (5  mg/L), trimethoprim (8  
mg/L) or linezolid (8  mg/L). Mutation frequencies were cal-
culated as the quotient of the numbers of colony-forming
units grown on selective and non-selective plates.
As shown inTable  1, the MICs of linezolid for S. aureus did
not exceed 2  mg/L, irrespective of resistance to oxacillin and
other classes of antibacterials and of relatedness to di¡erent
clonal groups,MRSA included.
The MICs for the majority of coagulase-negative staphylo-
cocci were one- to two-fold lower than those for S. aureus,
irrespective of resistance to oxacillin and other antibiotics
(Table  2).
The MRSA strains investigated in vitro exhibited di¡erent
spontaneous frequencies of mutants resistant to rifampicin
and to trimethoprim. No mutants resistant to linezolid could
be detected in vitro in broth cultures grown up to stationary
phase (Table  3).
In summary, theMICs of linezolid for S. aureus and for coa-
gulase-negative staphylococci are in the range of susceptibil-
ity.They are independent of resistance to other antibiotics and
clonal relatedness among S. aureus strains.These ¢ndings cor-
roborate data from a previous study [14]. Therefore, linezolid
appears to be a potential alternative for the treatment of infec-
tions with MRSA and multiresistant coagulase-negative sta-
phylococci.
Three of the MRSA strains investigated here probably pos-
sessed mutator alleles. As with strains exhibiting low frequen-
cies of other resistance mutants, in these strains no mutants
resistant to linezolid could be detected. This indicates that
spontaneous mutation to linezolid resistance is a rare event.
Previous studies have shown that linezolid is bacteriostatic
against Gram-positive cocci [15]. Nevertheless, initial clinical
studies have documented successful treatment of soft tissue
infections due to staphylococci [16].
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